Investing.com -- Genmab raised its full-year revenue and profit guidance on Thursday, driven by stronger-than-expected royalties from key partner drugs.

The company’s American depositary receipts (ADRs) rose more than 5% following the announcement.

The Danish biotech company now expects 2025 revenue between $3.5 billion and $3.7 billion, up from a previous range of $3.34 billion to $3.66 billion. It also raised its operating profit guidance mid-point by $100 million to $1.23 billion.

The upgrade was “driven by higher total royalty revenues from DARZALEX,” the company said.

Royalty revenue climbed 24% year over year in the first half to $1.38 billion, reflecting strong sales of Johnson & Johnson’s DARZALEX and Novartis’s Kesimpta.

Total revenue for the first six months of 2025 rose 19% to $1.64 billion, while operating profit jumped 56% to $548 million.

Genmab (NASDAQ:GMAB) also cited higher sales of its own cancer drug EPKINLY as a key driver of its performance. Meanwhile, net sales of DARZALEX rose 22% to $6.78 billion over the period.

“In the first half of the year, we continued to make progress towards our strategic priorities as we strive towards our goal of bringing our innovative therapies to additional patients in need,” said CEO Jan van de Winkel.

The company also highlighted encouraging trial data for its antibody-drug conjugate Rina-S in endometrial cancer and the continued rollout of Tivdak in Japan.

Related articles

Genmab raises full-year outlook, shares rise

Clients buying into summer rally, bracing for later pullback, says BofA's Hartnett

7 Undervalued Stocks on the Rise With 50%+ Upside Potential

View Comments